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Hedgehog signalling plays a fundamental role in the control of
metazoan development, cell proliferation and differentiation,
as highlighted by the fact that its deregulation is associated
with the development of many human tumours. SUFU is
an essential intracellular negative regulator of mammalian
Hedgehog signalling and acts by binding and modulating the
activity of GLI transcription factors. Despite its central
importance, little is known about SUFU regulation and the
nature of SUFU–GLI interaction. Here, the crystal and small-
angle X-ray scattering structures of full-length human SUFU
and its complex with the key SYGHL motif conserved in all
GLIs are reported. It is demonstrated that GLI binding is
associated with major conformational changes in SUFU,
including an intrinsically disordered loop that is also crucial
for pathway activation. These findings reveal the structure of
the SUFU–GLI interface and suggest a mechanism for an
essential regulatory step in Hedgehog signalling, offering
possibilities for the development of novel pathway modulators
and therapeutics.
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1. Introduction
The Hedgehog (Hh1) signalling pathway plays a key role
in directing cellular growth and tissue patterning during
embryonic development. Furthermore, in normal adult
physiology the pathway is implicated in stem cell maintenance,
tissue repair and regeneration. Perturbations in the pathway
thus lead to a wide range of developmental deficiencies and
have been implicated in several types of human cancers
(Nieuwenhuis & Hui, 2005; Jiang & Hui, 2008; Varjosalo &
Taipale, 2008; Barakat et al., 2010; Teglund & Toftga˚rd, 2010;
Ingham et al., 2011).
The start and end of the signalling cascade have been well
defined and are essentially conserved across species. A Hh
ligand binds to the membrane receptor Patched (Ptc), which in
the unliganded state represses another transmembrane
protein, Smoothened (Smo). This repression is relieved upon
ligand binding, allowing active Smo to regulate transcription-
factor activity. In mammals, it is the family of glioblastoma
(Gli) zinc-finger transcription factors, Gli1, Gli2 and Gli3, that
execute pathway activation and repression at the transcrip-
tional level. The intermediate steps of the pathway are less
well understood and diverge significantly between species.
The major mammalian regulator of Gli activity is the tumour
suppressor protein Suppressor of fused (Sufu; Kogerman et al.,
1999; Dunaeva et al., 2003; Merchant et al., 2004; Cheng & Yue,
2008). Whilst being completely dispensable for Drosophila
embryogenesis, this protein is absolutely essential for
1 Pathway components are abbreviated as follows: human, uppercase; mouse
and other vertebrates in general, uppercase first letter; Drosophila, lowercase.
mammalian development, since knockout of Sufu in mice
leads to continuous ligand-independent Hh signalling activity
and embryonic lethality at E9.5 (Cooper et al., 2005; Sva¨rd
et al., 2006). Furthermore, loss of human SUFU activity is
associated with multiple cancer forms. Germline SUFU
mutations have been found in patients with medulloblastoma
(Taylor et al., 2002; Slade et al., 2011; Brugie`res et al., 2012),
meningioma (Aavikko et al., 2012; Kijima et al., 2012) and
associated with Gorlin syndrome (Pastorino et al., 2009;
Kijima et al., 2012), a condition that creates a predisposition to
basal cell carcinoma. Moreover, somatic mutations and loss
have been found in medulloblastoma, chondrosarcoma and
rhabdomyosarcoma (Taylor et al., 2002; Tostar et al., 2006;
Tarpey et al., 2013).
Suggested models of how Sufu regulates Gli include its
sequestration in the cytoplasm (Kogerman et al., 1999), the
recruitment of a co-repressor complex to Gli-responsive
promoter regions of DNA (Cheng & Bishop, 2002) and
promotion of the conversion from activator to repressor forms
of Gli2 and Gli3 (Wang et al., 2010). Direct binding of Sufu to
all three Gli transcription factors has been well documented
(Kogerman et al., 1999; Pearse et al., 1999; Stone et al., 1999;
Dunaeva et al., 2003; Merchant et al., 2004) and dissociation
of the Sufu–Gli complex is a proposed key step in pathway
activation (Humke et al., 2010; Tukachinsky et al., 2010). The
exact nature of this interaction has however not been eluci-
dated, although Gli-binding properties have been ascribed to
both the N- and C-terminal regions of Sufu. In order to define
the molecular details of the Sufu–Gli interaction and advance
our knowledge of its regulation, we initiated a structural
analysis of these key components at the very basis of human
HH signalling.
2. Methods
2.1. Protein expression and purification
Bacterial expression constructs were assembled by
subcloning different SUFU32–483 variants into vector
pLJMBP4c (Monne´ et al., 2008). MBP-SUFU- and MBP-
SUFU-SH plasmids were generated by replacing amino acids
279–360 with the heptamer sequence PSRGEDP and a shuf-
fled IDR sequence, respectively (Supplementary Table S1a2).
The mutant MBP-SUFUR386A,R388A,H391A,R393A was obtained
through the GeneCust Europe DNA mutagenesis service.
MBP-SUFU constructs were expressed in Escherichia coli
JM109 (DE3) (Promega) at 21C. Protein expression was
induced at a cell density of OD550 = 0.5–1 with 0.1 mM IPTG
for 16–18 h. Cells from 1 l culture were suspended in 10 ml
50 mM Tris–HCl pH 7.5, 50 mM NaCl, 1 mM MgCl2, 1 mM
DTT, 0.2 mg ml1 lysozyme, 25 U ml1 Benzonase (Sigma–
Aldrich) and cOmplete Mini EDTA-free protease inhibitors
(Roche) and were disrupted using three freeze–thaw cycles.
Bacterial debris was removed by centrifugation at 18 000g for
30 min. Cleared lysates were loaded onto 5 ml HisTrap HP
columns (GE Healthcare). Following extensive washing with
50 mM Tris–HCl pH 7.5, 1 M NaCl, 20 mM imidazole, 1 mM
DTT, bound proteins were eluted with 50 mM Tris–HCl pH
7.5, 50 mM NaCl, 500 mM imidazole, 1 mM DTT. The eluate
was concentrated to 2–3 ml using Amicon Ultra centrifugal
filter units (Millipore) and further purified by size-exclusion
chromatography (SEC) on a HiPrep 26/60 Sephacryl S-200
HR gel-filtration column (GE Healthcare) equilibrated with
10 mM Tris–HCl pH 7.4, 50 mM NaCl, 1 mM DTT. Pooled
fractions containing monomeric MBP-SUFU protein were
concentrated as above and filtered using 0.2 mm Ultrafree-MC
centrifugal filter units (Millipore). Concentrated proteins were
flash-frozen in liquid N2 and stored at 80C.
Insect-cell expression of N-terminally His6-tagged
SUFU30–484 was performed using the Bac-to-Bac Baculovirus
Expression System (Invitrogen). Generation of recombinant
baculovirus stock was carried out according to the supplier’s
recommendations. Sf9 cells (Invitrogen) were cultured at 27C
in SF-900 II Serum Free Medium (Invitrogen) and infected
with recombinant baculovirus at mid-logarithmic phase
(106 cells ml1, viability 99%) using a multiplicity of infec-
tion of 1. After 72 h, cells were harvested by centrifugation
and stored at 80C until use. Pelleted cells from 1 l culture
were lysed in 20 ml 50 mM Tris–HCl pH 7.4, 150 mM NaCl,
5 mM MgCl2, 0.2% NP-40, 1 mM DTT, 25 U ml
1 Benzonase
and cOmplete Mini EDTA-free protease inhibitors (Roche)
using three freeze–thaw cycles. Following centrifugation at
20 000g for 1 h, cleared lysate was loaded onto a 5 ml HisTrap
HP column (GE Healthcare). After extensive washing with
50 mM Tris–HCl pH 7.5, 1 M NaCl, 20 mM imidazole, 1 mM
DTT, bound proteins were eluted with 50 mM Tris–HCl pH
7.5, 1 M NaCl, 500 mM imidazole, 1 mM DTT. The eluate was
loaded onto a HiPrep 26/60 Sephacryl S-200 HR column (GE
Healthcare) equilibrated with 10 mM Tris–HCl pH 7.4, 1 M
NaCl, 1 mM DTT. The protein was purified, concentrated,
filtered and stored as above.
2.2. Crystallization
MBP-SUFU-FL protein (12 mg ml1 in 10 mM Tris–HCl
pH 7.5, 50 mM NaCl, 1 mM DTT, 1 mM maltose) was crys-
tallized at 4C by hanging-drop vapour diffusion with 0.2 M
potassium/sodium tartrate, 0.1 M bis-tris propane pH 8.5,
16%(v/v) PEG 3350 (at a protein:mother liquor ratio of 2:1).
X-shaped crystals of 0.5 mm in width appeared after 5 d.
Crystals were transferred stepwise to a cryosolution equiva-
lent to the mother liquor plus an additional 4%(v/v) PEG 3350
and 10%(v/v) MPD, mounted in cryoloops and flash-cooled in
liquid N2.
Crystal form I of MBP-SUFU- (6.5 mg ml1 in 10 mM
Tris–HCl pH 7.5, 50 mM NaCl, 1 mM DTT, 1 mM maltose)
was obtained at 4C by hanging-drop vapour diffusion with
0.08 M sodium cacodylate pH 6.6, 20%(v/v) glycerol, 160 mM
calcium acetate, 9%(v/v) PEG 8000. Rod-shaped crystals of
200 mm in length appeared after 14 d. Specimens were washed
in a solution equivalent to the mother liquor, mounted in
cryoloops and flash-cooled in liquid N2.
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2 Supplementary material has been deposited in the IUCr electronic archive
(Reference: DW5072).
Crystal form II of MBP-SUFU- (11.6 mg ml1 in 10 mM
Tris–HCl pH 7.5, 50 mM NaCl, 1 mM DTT) was crystallized
by hanging-drop vapour diffusion at 4C with 0.1 M Na
HEPES pH 7.5, 17%(v/v) PEG 3350, 0.2 M NaCl. Rod-shaped
crystals appeared within days and were transferred stepwise
to a cryo-solution equivalent to the growth conditions plus an
additional 3%(v/v) PEG 3350 and 10%(v/v) MPD, mounted in
cryoloops and flash-cooled in liquid N2.
MBPA216H_K220H-SUFU-W61D_L62S_G63F_P453A_454–456_K457A
(10 mg ml1 in 10 mM Tris–HCl pH 7.5, 50 mM NaCl, 1 mM
DTT, 1 mM maltose) was mixed in a 1:1 molar ratio with zinc
acetate and a 1:4 molar ratio with GLI1p or GLI3p. Complexes
were crystallized by hanging-drop vapour diffusion at 4C with
1:1 or 2:1 drops of protein:well solution [14–18%(v/v) PEG
3350, 0.2 M sodium formate]. Irregular-shaped crystals which
grew out of precipitate were transferred stepwise to a cryo-
solution equivalent to the growth conditions plus an additional
10%(v/v) PEG 3350, mounted in cryoloops and flash-cooled in
liquid N2.
2.3. X-ray data collection
Diffraction data were collected at the European Synchro-
tron Radiation Facility (ESRF), Grenoble, France. Data were
collected from single crystals at 100 K using the following
beamlines and wavelengths: MBP-SUFU-FL, ID14-1
(Wakatsuki et al., 1998), 0.9334 A˚; MBP-SUFU- crystal form
I, ID23-1 (Nurizzo et al., 2006), 1.0723 A˚; MBP-SUFU-
crystal form II, ID23-2 (Flot et al., 2010), 0.8726 A˚;
MBPA216H_K220H-SUFU-W61D_L62S_G63F_P453A_454–456_K457A–
GLI1p and MBPA216H_K220H-SUFU-W61D_L62S_G63F_P453A_
454–456_K457A–GLI3p, ID29 (de Sanctis et al., 2012), 0.9762 A˚
(Table 1).
2.4. X-ray structure determination
The MBP-SUFU-FL and MBP-SUFU- data sets were
processed with iMosflm (Battye et al., 2011) and integrated
with SCALA (Evans, 2006) and TRUNCATE (French &
Wilson, 1978); the MBPA216H_K220H-SUFU-W61D_L62S_G63F_
P453A_454–456_K457A–GLI1p and MBPA216H_K220H-SUFU-
W61D_L62S_G63F_P453A_454-456_K4–7A–GLI3p data sets were
processed using XDS (Kabsch, 2010) in the xia2 pipeline
(Winter, 2010).
The structure of MBP-SUFU-FL was solved by molecular
replacement (MR) with Phaser (McCoy et al., 2007) using an
initial data set collected at 4.1 A˚ resolution {overall Rp.i.m. =
13.4%; outer shell [4.10–4.32 A˚, hI/(I)i = 2.1] Rp.i.m. = 37.9%};
the search models were the MBP molecule from chain A of
PDB entry 3d4g (residues Thr3–Ala371; Monne´ et al., 2008)
and the N-terminal domain of SUFU from chain A of PDB
entry 1m1l (residues Pro32–Asp262; Merchant et al., 2004). As
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Table 1
Crystallographic data-collection statistics.
Values in parentheses are for the highest resolution shell.
MBP-SUFU-FL
(PDB entry 4bl8)
MBP-SUFU-
crystal form I
(PDB entry 4bl9)
MBP-SUFU-
crystal form II
(PDB entry 4bla)
MBPA216H_K220H-SUFU-
W61D_L62S_G63F_P453A_
454–456_K457A–GLI1p
(PDB entry 4blb)
MBPA216H_K220H-SUFU-
W61D_L62S_G63F_P453A_
454–456_K457A–GLI3p
(PDB entry 4bld)
Beamline ESRF ID14-1 ESRF ID23-1 ESRF ID23-2 ESRF ID29 ESRF ID29
Wavelength (A˚) 0.9334 1.0723 0.8726 0.9762 0.9762
Temperature (K) 100 100 100 100 100
Detector ADSC MX-225 CCD MX-225 CCD PILATUS 6M-F PILATUS 6M-F
Crystal-to-detector distance (mm) 322 380 374 568 501
Rotation range per image () 1 1 1 0.05 0.1
Total rotation range () 91 506 180 180 180
Exposure time per image (s) 10 0.1 2 0.04 0.04
Space group P212121 [No. 19] P1 [No. 1] P21212 [No. 18] P21 [No. 4] P21 [No. 4]
Unit-cell parameters
a (A˚) 97.32 93.43 117.92 116.30 116.61
b (A˚) 99.55 103.28 372.57 137.60 136.55
c (A˚) 192.94 111.51 86.25 116.54 116.74
 () 90 63.67 90 90 90
 () 90 81.13 90 105.49 105.25
 () 90 76.03 90 90 90
Mosaicity () 0.72 0.35 0.40 0.24 0.14
Resolution (A˚) 49.78–3.04 (3.20–3.04) 30.00–2.80 (2.95–2.80) 39.58–3.50 (3.69–3.50) 62.73–2.80 (2.87–2.80) 46.36–2.80 (2.87–2.80)
Total No. of reflections 400319 676872 572793 296995 295196
No. of unique reflections 36846 87954 49033 85233 85722
Completeness (%) 99.9 (100.0) 98.6 (98.1) 99.9 (100.0) 98.2 (98.4) 99.0 (95.7)
Multiplicity 10.9 (11.1) 7.7 (7.8) 11.7 (12.5) 3.5 (3.6) 3.4 (3.4)
hI/(I)i 17.0 (2.0) 12.9 (2.0) 28.1 (2.2) 10.4 (1.4)† 9.6 (1.6)‡
CC1/2 0.999 (0.612) 0.997 (0.637) 0.999 (0.689) 0.998 (0.526) 0.996 (0.639)
R (%) 12.1 (139.5) 13.2 (113.6) 24.2 (202.1) 6.1 (77.1) 7.1 (66.7)
Rr.i.m. (%) 12.7 (146.3) 14.1 (121.7) 25.5 (210.8) 8.2 (103.8) 9.3 (91.9)
Rp.i.m. (%) 3.9 (43.7) 5.1 (43.4) 7.4 (59.5) 5.8 (71.6) 6.8 (62.2)
Overall B factor from
Wilson plot (A˚2)
102.0 78.3 91.6 94.1 89.6
† The mean I/(I) in the outer shell is 2.0 at 2.96 A˚ resolution. ‡ The mean I/(I) in the outer shell is 2.0 at 2.92 A˚ resolution.
in the case of MBP-ZP3 (Monne´ et al., 2008), correctness of
the solution was confirmed by clear difference electron density
for a molecule of d-(+)-maltose (coordinates for which were
not included in the search ensemble) within the ligand-binding
pocket of the two MBP molecules in the asymmetric unit. The
structure of the SUFU C-terminal domain was manually built
into A-weighted difference Fourier maps (Read, 1986) using
Coot (Emsley et al., 2010). Refinement against a maximum-
likelihood (ML) target was performed with phenix.refine
(Adams et al., 2010). Simulated annealing was initially used
with a starting temperature of 5000 K, and translation/
libration/screw (TLS) refinement of B factors was performed
during the final rebuilding cycles on the basis of TLSMD
(Painter & Merritt, 2006) analysis of individually refined
atomic displacement parameters; noncrystallographic
symmetry (NCS) restraints were kept during all refinement
steps based on manually determined local differences between
molecules. Riding H atoms were added with phenix.reduce and
used throughout; validation was performed using MolProbity
(Chen et al., 2010). The Ramachandran statistics were 98.0%
favoured, 2.0% allowed and 0.0% outliers.
The structure of MBP-SUFU- crystal form I was solved by
MR using the refined coordinates of MBP-SUFU-FL (MBP,
Glu5–Ala371; SUFU, Pro32–Leu278, Ile361–Asp449, Glu455–
Val478) as a search model. The MBP-SUFU- crystal form II
data were also phased by MR using the SUFU moiety of
MBP-SUFU-FL and the unliganded form of MBP (PDB entry
1omp, residues Lys1–Thr366; Sharff et al., 1992) as search
models; however, significant manual rebuilding was required
to model three of the four MBP moieties within the asym-
metric unit of this crystal (chains B–D), which are highly
disordered (average B factor = 272 A˚2) compared with the rest
of the structure (average B factor = 122 A˚2). The structure of
MBP-SUFU- crystal form II was refined using the refined
coordinates of crystal form I of the same construct as a
reference. The Ramachandran statistics for crystal form I were
98.0% favoured, 1.9% allowed and 0.1% outliers and those for
crystal form II were 97.8% favoured, 1.9% allowed and 0.3%
outliers.
The GLI1p and GLI3p complex structures were solved
by MR using the refined coordinates of MBP-SUFU- as a
search model; as in the case of the latter the structures were
refined and validated essentially as described for MBP-SUFU.
The Ramachandran statistics for the GLI1p complex were
97.9% favoured, 2.0% allowed and 0.1% outliers and those for
the GLI3p complex were 97.9% favoured, 2.1% allowed and
0.0% outliers. Figures were generated with PyMOL (Schro¨-
dinger) and LigPlot+ (Laskowski & Swindells, 2011). Supple-
mentary Video S1 was produced with PyMOL based on an
interpolation calculated by RigiMOL (Schro¨dinger).
2.5. Limited proteolysis
SUFU32–484 cloned in pLJMBP6c was expressed in E. coli
and purified as described above. The purified protein was
digested with trypsin (Sigma–Aldrich) in 100 mM ammonium
bicarbonate at 23C. The protease was inactivated by adding
10 mM PMSF and sample-loading buffer followed by heating
at 95C for 5 min. Protein bands were separated by SDS–
PAGE and visualized by Coomassie Blue staining. Proteolytic
peptide fragments were identified by N-terminal sequencing
(Alphalyse A/S) as well as MALDI–TOF and MALDI–TOF/
TOF mass-spectrometric analyses (Ultraflex II and Autoflex
III, Bruker Daltonics).
2.6. Hydrogen–deuterium exchange (HDX)
To compare amide HDX kinetics between MBP-SUFU-FL
and MBP-SUFU-, 4 ml of each protein (both at 11 mg ml1
in 50 mM Na HEPES pH 7.0, 50 mM NaCl, 5 mM -mercapto-
ethanol, 1.5 mM maltose) was mixed with 13 ml deuterated
buffer with the same ionic composition as the protein sample.
For MBP-SUFU-FL–Gli3p interaction experiments, 45 ml
MBP-SUFU-FL (11 mg ml1) was mixed with 5 ml Gli3p
(6 mM; a 5.5-fold excess) and incubated for 1 h. In the latter
case, exchange was initiated by mixing 4 ml MBP-SUFU-FL–
Gli3p with 13 ml deuterated buffer with the same ionic
composition as the sample. Each reaction was stopped by
adding 9 ml quenching solution (4 M urea, 50 mM TCEP, 1%
TFA) and flash-freezing in liquid N2. Deuteration reactions
were incubated for 60, 300, 600 and 1800 s for the MBP-
SUFU-FL and MBP-SUFU- experiments and 300, 600 and
1800 s for the MBP-SUFU-FL–Gli3p interaction experiments
(at 4C, in triplicate). A 24 h incubation was used as a fully
deuterated sample for back-exchange correction.
Samples were analyzed in a semi-automated HDX-MS
system (Biomotif AB, Sweden) in which manually injected
samples were automatically digested, cleaned and separated
at 1.0C. Deuterated samples were digested using a 1 min
stop-flow protocol (Poroszyme Immobilized Pepsin Cartridge,
Applied Biosystems, USA), followed by an online desalting
step with a 1.0  10 mm C-18 precolumn (ACE HPLC
Columns, UK) using 0.05% TFA at 300 ml min1 for 3 min.
Peptic peptides were then separated by a C18 Halo 2.1 
100 mm (Advanced Materials Technology, USA) or a
Chromolith FastGradient 50  2 mm for MBP-SUFU-FL/
MBP-SUFU- and MBP-SUFU-FL–Gli3p experiments,
respectively. Peptic peptides were separated by a 8.5 min
5–40% linear gradient of acetonitrile in 0.3% formic acid. An
Orbitrap XL mass spectrometer (Thermo Scientific, USA)
operated at 60 k resolution was used for the analysis.
Several LC MS/MS runs were carried out to identify MBP-
SUFU peptic peptides. The Mascot software (Matrix Science)
was used to search an MBP-SUFU sequence database.
Peptides with scores higher than 20 were selected for HDX
kinetic studies. In addition, each selected peptide was further
validated by manually inspecting the MS/MS spectrum. The
HDExaminer software (Sierra Analytics, USA) was used to
process all HDX MS data.
2.7. Small-angle X-ray scattering (SAXS)
SAXS data were collected on a Rigaku BioSAXS-1000
using Cu radiation ( = 1.5418 A˚) from a Rigaku FR-E+
SuperBright rotating-anode X-ray generator. The BioSAXS-
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1000 consists of an optic, a vacuum chamber and a detector.
The optic is a double-bounce Rigaku Confocal MaxFlux
multilayer optic specifically designed for the BioSAXS-1000
and it focuses the X-rays to a point at the detector. The
vacuum chamber contains a Kratky block, a sample holder
and a beamstop with an integrated PIN diode. The Kratky
block collimates the X-ray beam into the shape of a line that is
approximately 0.5 mm tall at the sample position; however,
the beam is focused to a point at the detector. SAXS data were
recorded using a DECTRIS PILATUS 100K detector and the
camera length was 0.5 m. The q range for all SAXS data was
from 0.01 to 0.68 A˚1.
All samples and buffers were loaded into 1.0 mm quartz
capillaries, placed under vacuum and measured at 20C.
Glucose isomerase was used as a secondary standard to assess
I(0) data. MBP-SUFU proteins used for SAXS were purified
from E. coli as described above, except that SEC was
performed in 50 mM Na HEPES pH 7.0, 50 mM NaCl, 5 mM
-mercaptoethanol, 1.5 mM maltose and only two fractions
from the peak were pooled for analysis (Supplementary Fig.
S1). The proteins were 99% pure as judged by Coomassie Blue
staining of an SDS–PAGE gel. SEC buffer passed through the
gel-filtration column immediately prior to protein purification
was used as the blank. Scattering data were measured from
frozen aliquots of MBP-SUFU that were thawed on ice,
centrifuged at 20 000g for 10 min, diluted in SEC buffer and
loaded into 1.0 mm diameter quartz capillaries. For experi-
ments with GLI peptide, MBP-SUFU- was mixed in a 1:10
molar ratio with GLI1p in the same buffer. Three concentra-
tions of each protein (between 1.1 and 7.3 mg ml1) were
measured to ensure that concentration effects did not influ-
ence data analysis. The protein concentration was determined
by measuring the absorbance at 280 nm with extinction
coefficients of 1.4073 for MBP-SUFU-FL and 1.5484 for MBP-
SUFU-. Each SAXS profile was the result of a 60 min
exposure in image-refreshing mode. In this mode, a 60 min
exposure was the sum of six consecutive 10 min exposures that
were individually inspected to ensure that radiation damage
was not present in the sample.
Initial data analysis, reduction of scattering images to one-
dimensional plots of intensity versus momentum transfer (q)
followed by buffer subtraction, was performed by the Rigaku
SAXSLab software package. Buffer-subtracted data were then
analyzed using the ATSAS program suite (Petoukhov et al.,
2012). Radius of gyration (Rg) values were determined from
Guinier plots in PRIMUS (Konarev et al., 2003) and pair
distance distribution functions, P(r), were computed with
GNOM (Svergun, 1992). Vc, QR and 
2
free were calculated
according to Rambo & Tainer (2013). Ab initio molecular
envelopes of MBP-SUFU were generated using DAMMIF
(Franke & Svergun, 2009). For MBP-SUFU-FL and MBP-
SUFU-, 15 independent DAMMIF models were aligned,
averaged and filtered using DAMAVER (Volkov & Svergun,
2003) and potential clusters were assessed with DAMCLUST
(Petoukhov et al., 2012). For MBP-SUFU-FL there were
clearly two clusters, each composed of seven models; the mean
normalized spatial discrepancy for the averaging of cluster 1
was 0.728  0.050 and that for cluster 2 was 0.729  0.063. For
MBP-SUFU- there was only a single cluster and the mean
normalized spatial discrepancy for the averaging was 0.722 
0.031. CRYSOL (Svergun et al., 1995) was used to calculate
the theoretical SAXS profile from each of the MBP-SUFU
crystal structure models and compare it with the experimental
SAXS profiles. The C-atom coordinates of SUFU residues
that are disordered in the MBP-SUFU-FL crystal structure
were modelled by performing nine independent runs of
CORAL (Petoukhov & Svergun, 2005; mean 2/2free values of
10.3  1.6 and 14.8  2.4), assuming the parts of MBP-
SUFU- remain fixed and using data to q = 0.3 A˚1. Crystal
structures and CORAL models were initially aligned to the
averaged SAXS envelopes using SUPCOMB and were
manually adjusted by rotation and translation thereafter. The
model of MBP-SUFU- that had the best fit to the average
SAXS envelope was assembled by fusing crystallographic
models of maltose-bound MBP and SUFU- in one specific
relative orientation observed in the 2.8 A˚ resolution apo
structure. The seven-residue loop which replaces the IDR in
SUFU- was then grafted from one of the molecules in the
3.5 A˚ resolution structure and energy-minimized with
YASARA Structure (Krieger et al., 2002) so that it properly
fitted the gap. The resulting optimized model agrees with the
scattering data as well as the original crystallographic models
of MBP-SUFU- do.
2.8. Microscale thermophoresis
A 5-FAM-labelled peptide (FAM-GLI1p) comprising resi-
dues 115–131 of GLI1 (Supplementary Table S1b) was
synthesized by Pepceuticals Ltd. A titration series of each
recombinant protein was prepared by serial 1:1 dilutions in
MST buffer (50 mM Tris–HCl pH 7.6, 150 mM NaCl, 10 mM
MgCl2, 0.05% Tween-20) and mixed in a 1:1 ratio with FAM-
GLI1p to give final concentrations of 50 nM FAM-GLI1p with
MBP-SUFU constructs in the ranges 14.2–29 070 and 54–
110 500 nM. Reactions were aspirated into glass capillaries
and the thermophoretic movement of FAM-GLI1p was
monitored using a Monolith NT.115 instrument (NanoTemper
Technologies; Wienken et al., 2010), with a laser on for 30 s
and off for 5 s and a laser power/voltage of 20% for MBP-
SUFU-FL and the MBP-SUFU-FL mutants, 40% for MBP-
SUFU- and 80% for MBP-SUFU-SH. Fluorescence was
measured before laser heating (FCold) and after 30 s of laser-on
time (FHot). The normalized fluorescence FHot/FCold reflects
the concentration ratio of labelled molecules. FHot/FCold was
plotted directly and multiplied by a factor of 10, yielding a
relative change in fluorescence per thousand. Kd was calcu-
lated from three independent thermophoresis measurements
using NanoTemper software (NanoTemper Technologies).
2.9. Production of Shh conditioned medium
293 EcR Shh cells (ATCC; Cooper et al., 1998) were
cultured in DMEM high-glucose (4.5 g l1) l-glutamine
medium (PAA Laboratories GmbH) supplemented with 10%
foetal bovine serum (FBS; Saveen Werner), 0.1 mM MEM
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non-essential amino acids (Sigma–Aldrich), 1 mM sodium
pyruvate (Sigma–Aldrich), 100 units ml1 penicillin and
100 mg ml1 streptomycin (PAA Laboratories GmbH). At 90–
100% confluency, cells were switched to medium containing
2% FBS and Shh production was induced with 1.5 mM
ponasterone A (Enzo Life Sciences). Conditioned medium
was collected after 24 h of induction, filtered through 0.22 mm
filters, flash-frozen in liquid N2 and stored at 80C.
2.10. Thermal stability assays
Recombinant MBP-SUFU proteins were diluted to 2.6 mM
in 50 mM Na HEPES pH 7.0, 50 mM NaCl, 5 mM -mercapto-
ethanol; the peptides GLI1p and GLI1p-SH (Supplementary
Table S1b), synthesized by Dr W. Mawby (University of
Bristol), were dissolved in the same buffer. Proteins were spun
at 14 000g for 20 min at 4C before adding SYPRO Orange
(Molecular Probes) to a final concentration of 6. Reaction
volumes of 25 ml were prepared in 96-well PCR plates with
2.2 mM protein/SYPRO Orange solution and, where applic-
able, 44 mM peptide. Plates were sealed with optical tape,
heated from 20 to 90C in 12 s 0.2C steps in an iCycler and
fluorescence was detected using an excitation wavelength of
470 nm and an emission wavelength of 570 nm.
2.11. Fluorescence experiments
Recombinant MBP-SUFU constructs were diluted to
2.5 mM in 50 mM Na HEPES pH 7.0, 50 mM NaCl, 5 mM
-mercaptoethanol and spun at 14 000g for 20 min at 4C
before the addition of SYPRO Orange to a final 5 concen-
tration of dye. The fluorescence of 100 ml samples was
measured in black 96-well plates (Nunc) using excitation at
 = 470 nm and emission at  = 570 nm. GLI1p or GLI1p-SH
peptides prepared in the same buffer as above were added in
the given ratios and mixed before a second reading was taken.
Readings post-peptide addition were divided by the corre-
sponding pre-peptide addition measurements to obtain
normalized results.
2.12. Co-immunoprecipitation and immunoblot analysis
Cos-7 cells were transfected separately with C-terminally
FLAG-tagged GLI1 in pCMV5 (Andersson et al., 1989) and
N-terminally Myc-tagged SUFU in pCMV-Script (Stratagene)
using Fugene 6 (Roche). 24 h after transfection, the cells were
lysed with 50 mM Tris–HCl pH 7.4, 150 mM NaCl, 1% NP-40,
0.25% sodium deoxycholate, 1 mMN-ethylmaleimide (Fluka),
1 mM dithiothreitol and cOmplete Mini protease inhibitors
(Roche). Normalized lysates were combined and pre-
incubated for 6 h. Co-immunoprecipitation was performed for
16 h using agarose-conjugated anti-FLAG M2 (Sigma–
Aldrich) and anti-Myc 9b11 (Cell Signaling) antibodies. The
beads were washed three times with 500 ml lysis buffer and the
bound protein was eluted by boiling the beads in SDS–PAGE
sample buffer and analyzed by Western blotting. Samples were
separated by SDS–PAGE, transferred to polyvinylidene
fluoride Immobilon-P membranes (Millipore) and probed
using anti-Myc 71D10 (Cell Signaling) or anti-Myc 9E10
(Santa Cruz) antibodies and anti-DYKDDDDK tag antibody
(Cell Signaling). Similar results were obtained in four inde-
pendent experiments.
2.13. Hh pathway activity measurements
SUFU variants with mutated IDR regions, the SUFU-,
SUFU-SH, SUFU-SH2 and SUFU-IDRfly constructs, were
generated by replacing amino acids 279–360 of N-terminally
Myc-tagged full-length SUFU in pcDNA3.1 (Invitrogen) with
corresponding sequences synthesized at GenScript USA Inc.
(Supplementary Table S1a). HEK 293 cells were transfected
with a mixture of GLI1-FLAG or Myc-GLI2 (Roessler et al.,
2005; a kind gift from Erich Roessler) and Myc-SUFU
constructs together with 12GLI-RE-TKO-luc luciferase
reporter (Kogerman et al., 1999) and pRL-SV40 (Promega)
internal control using Fugene 6 or X-tremeGENE 9 (Roche)
transfection reagent. Expression assays were carried out for
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Figure 1
Overall structure and topology of full-length human SUFU. (a) Crystal
structure of SUFU with the N-terminal domain coloured beige and the
C-terminal domain coloured according to (b). (b) Topology scheme, with
the intrinsically disordered region (IDR) represented by a dashed line.
48 h, followed by luciferase activity measurements using a
Dual Luciferase Activity Assay Kit (Promega). To verify the
expression levels of transfected SUFU and GLI constructs,
aliquots of cell lysates were separated by SDS–PAGE and
subjected to immunoblot analysis as above. The densities of
the visualized protein bands were quantified using the ImageJ
1.47v image-analysis and image-processing software
(Schneider et al., 2012).
Sufu/ mouse embryonic fibroblast (MEF) cells (Sva¨rd
et al., 2006) were transfected with a mixture of p8x30Gli-BS
LucII or p8x30Gli-mBS LucII reporter constructs (Sasaki et al.,
1997; generous gifts from Hiroshi Sasaki) together with pRL-
SV40 (Promega) internal control using Lipofectamine LTX
with Plus reagent (Invitrogen) according to the manufac-
turer’s instructions. Following transfection, Sufu/ MEF cells
were grown until the culture reached confluency (24–48 h) and
the cells were then switched to low-serum medium (0.5%
FBS) with 100–200 nM SAG (kindly provided by Jan
Bergman, Karolinska Institutet), 10 mM purmorphamine
(Calbiochem) or Shh conditioned medium (1:4) and grown
for an additional 48–72 h. Cell lysis and luciferase activity
measurements were performed using a Dual Luciferase
Activity Assay Kit (Promega). For statistical evaluation of
reporter gene assays, a one-tailed paired Student’s t-test was
used. All activity measurements were performed at least three
times in independent experiments.
3. Results
3.1. Structure of human SUFU
Although a crystal structure of an N-terminal domain of
SUFU has been reported (Merchant et al., 2004), no infor-
mation is available on its C-terminal region and how this is
arranged relative to the rest of the protein owing to difficulties
in producing soluble full-length recombinant protein. Here,
we have expressed an essentially full-length human SUFU
construct in E. coli by fusing it to an N-terminal maltose-
binding protein (MBP) molecule via a three-alanine linker
(Smyth et al., 2003; Monne´ et al., 2008). The fusion (MBP-
SUFU-FL), containing residues 32–483 of human SUFU and
a C-terminal hexahistidine tag, was purified by immobilized
metal ion affinity chromatography and size-exclusion chro-
matography (SEC), crystallized in the presence of maltose and
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Table 2
Crystallographic refinement statistics.
Values in parentheses are for the highest resolution shell.
MBP-SUFU-FL
(PDB entry 4bl8)
MBP-SUFU-
crystal form I
(PDB entry 4bl9)
MBP-SUFU-
crystal form II
(PDB entry 4bla)
MBPA216H_K220H-SUFU-
W61D_L62S_G63F_P453A_
454–456_K457A–GLI1p
(PDB entry 4blb)
MBPA216H_K220H-SUFU-
W61D_L62S_G63F_P453A_
454–456_K457A–GLI3p
(PDB entry 4bld)
Resolution (A˚) 48.66–3.04 (3.11–3.04) 29.48–2.80 (2.86–2.80) 39.58–3.50 (3.68–3.50) 19.98–2.80 (2.87–2.80) 19.94–2.80 (2.87–2.80)
Completeness (%) 99.9 98.6 99.9 98.2 99.0
No. of reflections in working set 34582 (2139) 85749 (5328) 46271 (6432) 82980 (5887) 83347 (5599)
No. of reflections in test set 2198 (123) 2191 (137) 2462 (362) 1963 (151) 1975 (135)
Final Rcryst (%) 20.0 (34.8) 20.0 (33.0) 25.9 (39.3) 19.7 (29.8) 20.1 (30.0)
Final Rfree (%) 24.6 (40.6) 23.4 (38.3) 29.3 (42.7) 23.4 (34.7) 23.4 (35.0)
No. of fusion protein molecules
in asymmetric unit
2 4 4 4 4
No. of non-H atoms†
Protein 11449 [5760] 22691 [11369] 22889 [11577] 22792 [11441] 22792 [11441]
Peptide 0 0 0 253 228
Maltose 46 92 0 92 92
Zn2+ ion 0 0 0 4 4
Total 11495 22783 22889 23141 23116
R.m.s. deviations‡
Bond lengths (A˚) 0.01 [0.01] 0.01 [0.01] 0.01 [0.01] 0.01 [0.01] 0.01 [0.01]
Bond angles () 0.90 [0.97] 0.85 [0.92] 1.25 [1.25] 0.10 [1.05] 1.14 [1.11]
Chirality (A˚3) 0.055 [0.062] 0.046 [0.051] 0.058 [0.059] 0.041 [0.044] 0.069 [0.067]
Planarity (A˚) 0.004 [0.005] 0.005 [0.005] 0.011 [0.011] 0.005 [0.005] 0.006 [0.005]
Dihedral angles () 13.39 [14.22] 12.52 [13.17] 11.90 [12.81] 11.38 [11.81] 12.48 [12.55]
B factors† (A˚2)
Protein 106 [109, 103] 71 [76, 67] 178 [242, 115] 100 [92, 107] 97 [91, 103]
Peptide N/A N/A N/A 95 90
Maltose 73 60 N/A 67 66
Zn2+ ion N/A N/A N/A 88 68
ML estimate for coordinate
error (A˚)/phase error ()
0.43/26.4 0.36/26.4 0.61/32.2 0.41/28.4 0.39/28.6
Ramachandran plot‡ (%)
Favoured 98.0 [99.3, 96.8] 98.0 [98.8, 97.2] 97.8 [99.0, 96.7] 97.8 [98.8, 96.9] 97.8 [98.3, 97.4]
Allowed 2.0 [0.7, 3.2] 1.9 [1.2, 2.5] 1.9 [1.0, 2.7] 2.1 [1.2, 2.8] 2.2 [1.7, 2.6]
Outliers 0.0 [0.0, 0.0] 0.1 [0.0, 0.3] 0.3 [0.0, 0.6] 0.1 [0.0, 0.3] 0.0 [0.0, 0.0]
† Values relative to the MBP and SUFU moieties of the MBP fusion proteins are shown in square brackets. ‡ Values relative to the MBP and SUFU (including GLI peptides, if
present) moieties of the MBP fusion proteins are shown in square brackets.
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the structure was determined to 3.0 A˚ resolution (R = 20.0%,
Rfree = 24.6%; Fig. 1a and Table 2). The N-terminal domain
exhibits the same structure as previously determined
(Merchant et al., 2004), despite the presence of the N-terminal
MBP fusion partner. The C-terminal region folds into a
domain that comprises a four-stranded and a six-stranded
-sheet, both with mixed topologies, which are connected by
two antiparallel -helices (Figs. 1a and 1b). This is a novel
protein fold, with only weak structural similarity (DALI
Z-scores of 2.7–2.8; Holm & Rosenstro¨m, 2010) to proteo-
somal Jab1/MPN domain proteins (PDB entries 1oi0 and 1r5x;
Tran et al., 2003; Ambroggio et al., 2004). The first helix in the
C-terminal domain of SUFU (helix 6) is bent and interacts
with helix 5 via residues Arg386, Arg388, His391 and Arg393
(Fig. 2a), thus forming a five-helix bundle comprising three
helices from the N-terminal domain and two helices from
the C-terminal domain. These interactions explain why the
C-terminal domain could not be expressed alone and are
consistent with the observation that mutation of the above
residues causes protein aggregation, probably owing to
misfolding (Fig. 2b).
3.2. SUFU contains an intrinsically disordered region
Although the crystallized protein was intact (Supplemen-
tary Fig. S2a), both SUFU molecules in the orthorhombic
asymmetric unit show no apparent density for the C-terminal
domain residues 279–360, suggesting that this region of the
molecule is highly mobile. Since disorder often impacts crystal
diffraction quality, we generated a new construct (MBP-
SUFU-) in which these 82 residues were replaced with a
shorter seven-residue loop (Supplementary Table S1a). This
construct was expressed and purified in the same way as MBP-
SUFU-FL and crystallized both in the presence (crystal form
I) and absence (crystal form II) of maltose. The corresponding
structures were determined to 2.8 A˚ resolution (R = 20.0%,
Rfree = 23.4%) and 3.5 A˚ resolution (R = 25.9%, Rfree =
29.3%), respectively (Table 2). Both crystal forms contain four
molecules in the asymmetric unit, with pairs assuming a head-
to-tail arrangement identical to that observed in the structure
of MBP-SUFU-FL (Supplementary Fig. S2b). The fold of
MBP-SUFU- is essentially the same as for the full-length
protein, demonstrating that the disordered residues are not
critical for protein folding or overall stability.
To determine whether the unobserved region in the
C-terminal domain is also disordered in solution, we subjected
MBP-SUFU-FL to limited proteolysis with trypsin (Receveur-
Bre´chot et al., 2006). Several protease-hypersensitive sites
were found clustered within residues 299–363, a stretch almost
exactly overlapping the region of missing density in the crystal
structure (Figs. 3a and 3b). Likewise, hydrogen/deuterium-
exchange (HDX) analysis (Brock, 2012; Brudler et al., 2006) of
the same region shows that it is highly sensitive to deuteration
Figure 2
Interaction between the N- and C-terminal domains is essential for the solubility of heterologous SUFU. (a) Interactions between residues in the five-
helix bundle formed between the two domains. (b) Size-exclusion chromatography profiles; the open and filled arrows indicate peaks corresponding to
aggregated protein eluted with the void volume and soluble monomeric protein, respectively.
(Supplementary Figs. S3a and 4). Moreover, limited proteo-
lytic fragment patterns of human SUFU expressed in insect
and bacterial cells are essentially identical (Supplementary
Fig. S5). Collectively, these data suggest that residues 279–360
constitute an intrinsically disordered region (IDR) that is an
inherent feature of native human SUFU. In cases such as these
when crystallography only reveals part of the picture, SAXS
is a useful complementary technique which can be used to
examine the conformation of disordered regions in solution
(Putnam et al., 2007). Interestingly, SAXS comparison of
MBP-SUFU-FL and MBP-SUFU- indicates that the IDR
forms a flexible protrusion from the C-terminal domain that
covers its -sheet 1 (Figs. 3c and 3d, Supplementary Fig. S6
and Supplementary Table S2). The latter is confirmed by the
HDX data, which show protection of the same sheet as well as
an N-terminal domain loop exposed on the same surface of the
molecule in MBP-SUFU-FL but not in MBP-SUFU- (Fig. 3c
and Supplementary Figs. S3 and 4).
To determine whether the IDR affects the GLI-binding
properties of SUFU, we used a human GLI1-derived peptide
(GLI1p; residues 115–131; Supplementary Table S1b)
containing the highly conserved SYGH motif important for
interaction with SUFU (Dunaeva et al., 2003) in a thermal
stability assay with MBP-SUFU-FL and MBP-SUFU-
(Fig. 4a). The addition of GLI1p stabilized both proteins: Tm
for MBP-SUFU-FL was shifted by 4C and that for MBP-
SUFU- was shifted by 3.6C. No stabilization was provided
by a control peptide comprising the same residues randomly
shuffled (GLI1p-SH; Supplementary Table S1b). Interestingly,
MBP-SUFU-FL exhibited high initial fluorescence values
upon addition of GLI1p, but no such effect was observed with
either MBP-SUFU- or a third construct which was identical
to MBP-SUFU-FL except that the 82 residues of the IDR
were shuffled (MBP-SUFU-SH; Supplementary Table S1a).
The GLI1 dose dependency of this effect was confirmed in a
separate experiment with increasing GLI1p concentrations
(Supplementary Fig. S7a). Furthermore, MBP-SUFU-FL was
more stable (Tm = 50.1
C) than both the MBP-SUFU- (Tm =
46.6C) and MBP-SUFU-SH (Tm = 47.7C) constructs. Taken
together, these data show that despite being apparently
disordered the IDR has properties which are different from
those of a random loop and alter upon GLI1p peptide binding.
The affinity of the three SUFU constructs for GLI1p was
determined more accurately using a FAM-labelled GLI1p
peptide (FAM-GLI1p; Supplementary Table S1b) in micro-
scale thermophoresis (Wienken et al., 2010) experiments
(Fig. 4b). The Kd values derived for all three constructs were
comparable; however, the thermophoretic properties of the
peptide were modified differently: whereas binding to MBP-
SUFU-FL increased the rate of movement in the thermo-
phoretic gradient, binding to MBP-SUFU- or MBP-SUFU-
SH decreased it. Since thermophoretic mobility is affected by
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Figure 3
SUFU contains an intrinsically disordered region. (a, b) Trypsin digest analysis of MBP-SUFU-FL. Open green rectangles indicate structured parts of the
protein in our crystallographic model. The red rectangles FR1–FR5 represent proteolytic fragments. (c, d) Fit of MBP-SUFU-FL and MBP-SUFU-
crystal structures into average ab initio envelopes calculated from SAXS data. MBP, blue; SUFU N-terminal domain, beige; SUFU C-terminal domain,
green. Residues of the IDR, built by CORAL, are shown in black. Peptides that are more protected from HDX in MBP-SUFU-FL than in
MBP-SUFU- are shown in pink.
the molecular charge, size and solvation shell (Wienken et al.,
2010) and because MBP-SUFU-FL and MBP-SUFU-SH have
the same theoretical size and charge, these data further
suggest that the native IDR behaves differently to a random
sequence of residues upon GLI1p binding.
Additional evidence of the distinct structural properties
of the IDR was provided by SDS–PAGE analysis of SUFU
expressed in either mammalian cells or bacteria. Despite
having identical amino-acid composition, full-length SUFU
(SUFU-FL) displays different electrophoretic mobility to two
SUFU constructs in which IDR residues are alternatively
shuffled (SUFU-SH and SUFU-SH2; Supplementary Table
S1a and Supplementary Figs. S7b and 7c). Anomalous mobi-
lity in SDS–PAGE has been described for proteins with post-
translational modifications, atypical amino-acid composition
and disordered segments (Iakoucheva et al., 2001). Mass-
spectrometric analysis has not revealed any post-translational
modifications in MBP-SUFU-FL peptides, including peptides
involving Ser342 and Ser346 (data not shown), which are
residues that have been reported to be targets for
phosphorylation in mammalian cells (Chen et al., 2011).
Together, these data suggest that disparities in electrophoretic
migrations are most likely to be owing to distinct structural
properties of the native IDR.
3.3. Structure of SUFU in complex with GLI peptides
In order to determine how SUFU interacts with GLI
transcription factors, we attempted to co-crystallize MBP-
SUFU-FL and MBP-SUFU- with GLI1p as well as corre-
sponding peptides from human GLI2 (GLI2p; residues 267–
283) and GLI3 (GLI3p; residues 328–344) (Supplementary
Table S1b). Despite extensive screening, these attempts were
unsuccessful. Therefore, the residues WLG61–63 of SUFU
were mutated to DSF in MBP-SUFU- to disrupt crystal
contacts between a loop within the SUFU N-terminal domain
and residues in the C-terminal domain (Supplementary Fig.
S2b) previously implicated in GLI binding (Merchant et al.,
research papers
2572 Cherry et al.  Hedgehog signalling regulation Acta Cryst. (2013). D69, 2563–2579
Figure 4
The SUFU IDR has distinct structural properties. (a) Thermal stability assays of MBP-SUFU constructs performed in triplicate, either alone (blue) or
with GLI1p (red) or GLI1p-SH (green). All constructs bind to GLI1p; however, MBP-SUFU-FL has different physical properties upon initial GLI1p
binding, as shown by the marked increase in fluorescence. (b) Microscale thermophoresis experiments with FAM-GLI1p and titrated MBP-SUFU
constructs, showing an average of three separate experiments. All proteins have similar affinity, but the thermophoretic properties of FAM-GLI1p are
modified differently between the MBP-SUFU-FL construct and the MBP-SUFU- and MBP-SUFU-SH constructs, reflecting a difference in shape.
2004). Furthermore, another flexible loop in SUFU was
shortened and residues 216 and 220 in the MBP moiety were
mutated to histidine in order to promote metal ion-mediated
crystallization of the fusion protein (Laganowsky et al.,
2011). The resulting construct, MBPA216H_K220H-SUFU-
W61D_L62S_G63F_P453A_454–456_K457A, produced crystals with
GLI1p and GLI3p that diffracted to 2.8 A˚ resolution (R =
19.7%, Rfree = 23.4% and R = 20.1%, Rfree = 23.4%, respec-
tively). Crystals with both peptides belonged to space group
P21 and contained four molecules in the asymmetric unit
which all exhibited a rotation, via a flexible linker, of 58
relative to the apo crystal structures (Fig. 5a and Supple-
mentary Video S1). Each molecule had clear density for the
peptide between domains (Fig. 5b). Peptide modelled into this
density forms a -strand clamped between the two domains,
creating one continuous 13-strand -sheet spanning both
domains. Interactions between SUFU His164 and Glu376
secure the closed conformation (Fig. 6a). HDX protection
analysis and SAXS experiments confirmed that this protein/
peptide conformation occurs in solution and is not a crystal-
lization artifact (Fig. 7, Supplementary Table S2 and Supple-
mentary Figs. S6, S8 and S9). In both structures the GLI
peptide fits snugly into a narrow channel with the histidine
from the SYGH motif (Dunaeva et al., 2003; His123 in GLI1
and His336 in GLI3) protruding into a pocket where it forms
hydrogen-bonding interactions with Tyr147 and Asp159
(Figs. 6b and 6c and Supplementary Table S3). The mutation
of Tyr147, Asp159 or Glu376 in MBP-SUFU-FL abolished
detectable binding to GLI1p in the microscale thermophoresis
assay (data not shown). To determine whether these binding
differences were translated into functional differences in the
cell, we examined the transcriptional activity of GLI1 in HEK
293 cells transiently transfected with mutated SUFU
constructs (Fig. 6d). The mutation of Asp159 and Tyr147 had a
significant effect on the ability of SUFU to repress GLI,
whereas the mutation of Glu376 and His164 had a smaller
effect. A similar pattern was observed in experiments
measuring constitutive Hh pathway activity in Sufu/ MEFs
(Fig. 6e). Notably, the leucine immediately following the GLI
SYGH motif, which is also completely conserved, packs tightly
into a hydrophobic pocket formed by SUFU residues Val269,
Ala271 and Leu380 (Fig. 6b). The following serine (conserved
except in Xenopus and Ciona) is hydrogen bonded to Glu376.
In agreement with these observations, a GLI3 peptide that
terminates at His336 (GLI3p-SHC; residues 328–336; Supple-
mentary Table S1b) is unable to protect MBP-SUFU-FL from
deuteration in HDX experiments (data not shown). Hence,
the critical binding motif extends beyond that previously
described (Dunaeva et al., 2003).
3.4. Regulatory role of the SUFU IDR
The observed physical differences between MBP-SUFU
constructs with and without the IDR suggest a functional role
of this domain. In agreement with the thermophoresis data,
there was no remarkable difference in GLI1 binding observed
in co-immunoprecipitation (Co-IP) experiments with SUFU-
FL, SUFU-SH and SUFU- (Fig. 8a). Similarly, transcrip-
tional activity induced by both GLI1 and GLI2 was efficiently
repressed by SUFU-FL, SUFU- and SUFU-SH in transient
transfection assay experiments (Fig. 8b and Supplementary
Figs. S10a and S10b), and deletion of the IDR had no
considerable effect on repression of the constitutive Hh
pathway activity in Sufu/ MEFs (Fig. 8c). Collectively, these
results imply that the IDR in SUFU is dispensable for GLI
binding and repression activity in cells without upstream
pathway activation.
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Figure 5
Crystal structure of MBPA216H_K220H-SUFU-W61D_L62S_G63F_P453A_454–
456_K457A in complex with GLI3p. (a) Superposition of the N-terminal
domains of apo (yellow with grey linker) and peptide-bound (beige,
N-terminal domain; green, C-terminal domain; purple linker) structures
shows a 58 rotation of the C-terminal domain via a flexible linker. (b)
The position of GLI3p in the MBP-216H_220H_-SUFU-W61D_L62S_G63F_
P453A_454–456_K457A–peptide co-crystal. An averaged kick OMIT map
contoured at 3.0 shows well defined density for GLI3p lying between the
-sheets of the SUFU N-terminal domain (beige) and C-terminal domain
(green).
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Figure 6
Mechanism of GLI binding. (a, b, c) Interactions between MBPA216H_K220H-SUFU-W61D_L62S_G63F_P453A_454–456_K457A and GLI3p. (a) The peptide
(blue) is clamped between the N-terminal (beige) and C-terminal (green) domains. (b) GLI3p (blue residue labels) binds in a channel with His336 and
Lys337 protruding into deep pockets. (c) SUFU–GLI3p interactions, with side-chain hydrogen bonds highlighted in yellow, and comparison of GLI1p and
GLI3p. Residues that are conserved in GLI1, GLI2 and GLI3 are shown in red. Blue boxes indicate residues with visible electron density. (d, e)
Mutations around the GLI3p binding site have varying effects on the ability of SUFU-FL to repress GLI1-induced reporter gene activity in HEK 293
cells (d) and to suppress constitutive pathway activity in Sufu/ cells (e).
The versatile nature of IDRs makes them ideal for the
formation of protein–protein interactions, and intrinsically
disordered stretches often function as regulatory platforms in
proteins (Babu et al., 2011). Hence, we set out to test whether
the SUFU IDR has a role in pathway reactivation in Sufu/
MEFs. While activation of cells with SMO agonist (SAG), a
Hh pathway activator upstream to SUFU, overrode repression
by the full-length protein, it failed to reactivate the pathway in
the presence of SUFU- or SUFU-SH (p 	 0.005, n = 10 and
p	 0.01, n= 4, respectively; Fig. 8d). Purmorphamine, another
small-molecule SMO agonist, as well as Sonic Hedgehog (Shh)
had the same disparate effects on SUFU-FL and SUFU-
repressive function (p 	 0.05, n = 5 and p 	 0.005, n = 9 for
purmorphamine and Shh, respectively; Supplementary Figs.
S10c and S10d). Collectively, these results are in agreement
with a simple model in which Hh activation in mammalian
cells is achieved via an IDR-dependent repression of SUFU
function (Fig. 8e).
The role of Sufu in the regulation of Hh signalling has
diverged between vertebrates and invertebrates (Varjosalo et
al., 2006). Whereas mammalian SUFU is a major negative
regulator and knockout of its gene is lethal (Cooper et al.,
2005; Sva¨rd et al., 2006), Drosophila Sufu has only a minor role
and loss-of-function mutations have no phenotype (Pre´at,
1992). Sequence alignment reveals that the IDR is the most
divergent region between human and Drosophila Sufu, with
only 11% sequence conservation compared with 42% in the
rest of the protein. However, despite the lack of sequence
conservation, this region of Drosophila Sufu is also predicted
to have relatively little secondary structure (Supplementary
Fig. S11). To test whether the regulatory role of SUFU IDR is
conserved between human and fly, we created a chimeric
SUFU construct in which amino acids 279–360 of human
SUFU were replaced with the corresponding region from
Drosophila Sufu (residues 275–340; SUFU-IDRfly; Supple-
mentary Table S1a). Similarly to SUFU- and SUFU-SH,
SUFU-IDRfly was able to repress GLI activity, but repression
could not be relieved by the addition of SAG (Fig. 8d). Hence,
the evolution of the IDR in SUFU may be closely linked to the
differing role of Sufu between species.
4. Discussion
In this study, we have determined the structure of full-length
human SUFU, an essential negative regulator of mammalian
Hedgehog signalling, alone and in complex with GLI peptides
representing the major conserved SUFU interaction partners.
The data provide new mechanistic insights into the inner
workings of one of the key signalling pathways governing
tissue patterning during embryonic development and deter-
mining cell fate and phenotype. Hitherto available knowledge
at the structural and biophysical level has mainly been focused
on receptor components in the upper part of the pathway
(Beachy et al., 2010), including the recent description of the
structure of the GPCR-like receptor protein SMO (Wang et
al., 2013). In contrast, little is known about the evolutionarily
conserved intracellular core pathway components that act
further downstream, such as SUFU and GLI. A structure of
the N-terminal half of SUFU was reported (Merchant et al.,
2004) that is confirmed in the present study, whereas for GLI
only the structure of the DNA-binding zinc-finger domain is
known (Pavletich & Pabo, 1993).
Studies aimed at the identification of protein regions
involved in Sufu–Gli interaction have suggested that the
N- and C-terminal regions of Sufu interact separately with the
C- and N-terminal regions of Gli, respectively (Ding et al.,
1999; Merchant et al., 2004; Barnfield et al., 2005). In contrast,
the structures of our SUFU–GLI peptide complexes show that
both the N- and C-terminal halves of SUFU interact simul-
taneously with a major evolutionarily conserved SUFU-
binding motif, including the amino acids SYGH, within the
N-terminal half of GLI (Dunaeva et al., 2003). Importantly,
recent studies have established the regulated dissociation of
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Figure 7
MBP-SUFU and GLI peptides interact in the same way in solution as in
crystals. (a) HDX analysis of MBP-SUFU-FL with GLI3p (blue). Areas
that are more protected from exchange in the presence of the peptide are
highlighted in pink. (b) Comparison of SAXS envelopes for MBP-
SUFU- in the absence (left) and presence (right) of GLI1p. Crystal
structures of apo MBP-SUFU- and of MBPA216H_K220H-SUFU-
W61D_L62S_G63F_P453A_454–456_K457A co-crystallized with GLI3p super-
pose well on apo and holo SAXS envelopes, respectively.
Sufu and Gli2/3 as a central step in the triggering of pathway
activity by Hh ligands in a manner dependent on the presence
of intact primary cilia (Humke et al., 2010; Tukachinsky et al.,
2010). Our present results reveal an intriguing mechanism at
the molecular level for the regulation of this fundamental step
in the mammalian Hh signalling pathway (Fig. 8e). We show
that in the unbound form SUFU adopts an open conformation
in which the IDR hovers over the surface of SUFU that
interacts with the N-terminal domain of GLI proteins. Upon
GLI binding, SUFU undergoes a large conformational change
in which the N- and C-terminal domains come together to
clamp highly conserved GLI residues in the middle of a large
-sheet (Supplementary Video S1). The important functional
role of amino acid Asp159 in the N-terminal domain of SUFU,
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Figure 8
The IDR regulates SUFU activity. (a) SUFU-FL (FL), SUFU- () and SUFU-SH (SH) all bind GLI1 when co-expressed in Cos-7 cells, as shown by
Co-IP. (b, c) SUFU-FL and SUFU- repress GLI1-induced reporter gene activity in HEK 293 cells (b) and suppress constitutive pathway activity in
Sufu/ cells (c) with similar efficiency. (d) SUFU-, SUFU-SH and SUFU-IDRfly (IDRfly) expressed in Sufu
/ cells are unable to mediate Hh pathway
reactivation induced by the SMO agonist SAG. Error bars indicate the range of data in three parallel samples. (e) Schematic model of the regulatory role
of SUFU with and without an intact IDR. Green and red colours indicate activated and repressed states of proteins, respectively.
as shown here and in the study by Merchant et al. (2004), is
explained by critical hydrogen-bonding interactions with a
conserved histidine residue in GLI (Figs. 6b and 6c). More-
over, the tight packing of the leucine next to the histidine in
GLI with SUFU residues, coupled with the importance of this
leucine in the protection of SUFU from deuteration, strongly
suggest that the minimal SUFU binding motif in GLI
encompasses the amino acids SYGHL.
Of particular interest is the finding that SUFU contains an
intrinsically disordered domain that is rearranged upon GLI
peptide binding. This suggests that SUFU acts as a central
signal organizer in a protein-interaction network in which the
IDR plays a key role in modulation of allostery or regulated
autoinhibition, properties that are found to be common
among proteins with intrinsic disorder and that hence exist in
many different structural states (Ferreon et al., 2013; Trudeau
et al., 2013). The observed regulatory role of the SUFU IDR
in relaying an HH signal may thus be owing to an allosteric
function induced by post-translational modifications or inter-
action of the IDR with a new partner protein causing a change
in the binding affinity between SUFU and GLI. Alternatively,
it is possible that the IDR has a role in determining intra-
cellular localization or that the SUFU IDR may act as an
inhibitory module with regard to SUFU–GLI binding, as
suggested by the observation that in the structure of SUFU
alone the IDR appears to shield the GLI-binding surface of
the protein. We propose that the IDR acts as a gatekeeper,
which in the rearranged conformation becomes a target for
HH-dependent regulatory factors facilitating the release of
GLI from SUFU.
A remaining challenge is to identify the signals involved and
to understand at the molecular level how activation of SMO
couples to SUFU–GLI dissociation. Interestingly, amino-acid
residues present within the IDR can serve as targets for
phosphorylation by PKA and GSK3 (Ser342 and Ser346)
and for ubiquitylation (Lys321) (Chen et al., 2011; Kim et al.,
2011). However, the phosphorylation of these residues does
not appear to be induced by the HH ligand and rather leads to
a stabilization of SUFU (Chen et al., 2011), implying a possible
role in determining the level of overall HH responsiveness.
The functional implication of the ubiquitination of Lys321 is
presently unknown.
In evolutionary terms, it appears that whereas the Sufu–Gli
association promoting generation of Gli repressor forms is
conserved, the relative importance and regulatory mechan-
isms have diverged (Ingham et al., 2011). In line with this view,
we find that fly sufu is nonfunctional in mammalian cells (data
not shown) and in particular that the predicted fly IDR is
unable to functionally replace its human counterpart.
Consistently, fly smo is unable to mediate transcriptional Hh
pathway activation in mammalian cells in culture (Bijlsma et
al., 2012). These observations suggest that divergence of the
regulatory mechanism impinging on the Sufu IDR is a major
factor underlying the species difference in Sufu function.
SUFU is a tumour suppressor protein that is found to be
inactivated most frequently (up to 50%) by germline muta-
tions in children below the age of three presenting with
medulloblastoma of the desmoplastic/nodular subtype (Slade
et al., 2011; Brugie`res et al., 2012), whereas a somatic mutation
frequency of about 10% has been reported for sporadic
medulloblastomas of the desmoplastic subtype (Taylor et al.,
2002). Moreover, germline or somatic mutations in the SUFU
gene have recently been described in association with
meningioma and chondrosarcoma (Aavikko et al., 2012;
Kijima et al., 2012; Tarpey et al., 2013), again involving tissue
types in which HH signalling is known to play a central role in
normal development. As expected for a tumour suppressor,
the vast majority of mutations are truncating and only two
missense mutations have so far been reported. In a family
predisposed to meningiomas, an R123C mutation segregated
with tumour development and loss of the wild-type allele was
detected in all tumours analyzed (Aavikko et al., 2012). This
mutation eliminates hydrogen bonding to Asp182 and Gln199,
suggesting a negative effect on SUFU folding and/or stability
that is consistent with the reduced inhibitory activity observed
in cellular assays. M141R, a second germline missense muta-
tion detected in a young child with a medulloblastoma of the
extensive nodularity subtype (Brugie`res et al., 2012), affects
hydrophobic interactions between an -helix and a -sheet
within the N-terminal half of SUFU. This also suggests an
indirect effect of the amino-acid substitution on SUFU–GLI
interaction.
Drug development efforts aimed at inhibiting the HH
pathway in tumour cells have hitherto been focused on the
GPCR-like receptor SMO. Unfortunately, the clinical effect of
drugs that target this protein may only last for a few months
(Rudin et al., 2009) owing to the rapid insurgence of drug-
resistant cancer cells carrying mutations in SMO itself (Yauch
et al., 2009). Moreover, a number of mechanisms, in addition
to SUFU mutations, that induce HH pathway activation
independently of the ligand/receptor level or the presence of
primary cilia have been described. This suggests that compo-
nents at the bottom of the pathway may constitute a better
target for the treatment of cancers dependent on active HH
signalling. The detailed structural description of the SUFU–
GLI complex and the identification of the SUFU IDR as a key
regulatory module reported here open precisely this possibi-
lity. At the same time, they provide information that could be
exploited to develop novel approaches for transient activation
of the pathway in the regenerative medicine setting.
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